Influx Health.

Why is Influx Healthtech Ltd falling/rising?

As of 20-Jun, Influx Healthtech Ltd's stock price is at 239.75, reflecting a decline of 0.1% and significant underperformance compared to the sector. The stock has dropped 13.65% over the past month, with mixed moving averages and decreased investor participation contributing to its downward trend.

As of 20-Jun, Influx Healthtech Ltd's stock price is falling, currently at 239.75, which reflects a decrease of 0.25 (-0.1%). This decline is evident as the stock has underperformed compared to the sector, with a performance today that is down by 0.82%. Over the past week, the stock has shown a modest increase of 0.67%, but this is overshadowed by a significant drop of 13.65% over the past month, while the benchmark Sensex has gained 1.67% in the same period.<BR><BR>Additionally, the stock's moving averages indicate mixed performance; it is higher than the 100-day and 200-day moving averages but lower than the 5-day, 20-day, and 50-day moving averages, suggesting recent weakness. Furthermore, there has been a decline in investor participation, with a delivery volume of 21.6k on June 18, which is down by 7.22% compared to the 5-day average. This decrease in trading activity may contribute to the downward pressure on the stock price. Overall, these factors indicate that Influx Healthtech Ltd is experiencing a decline in its stock price.

Which are the latest news on Influx Health.?

What does Influx Health. do?

Influx Healthtech Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 537 Cr. It currently has no reported sales or profits, a P/E ratio of 26.00, and a return on equity of 20.39%.

Overview: Influx Healthtech Ltd operates within the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: The incorporation year and any status changes are not provided. There are no sales or profit reports available for the latest quarter.<BR><BR>Financial Snapshot: Most recent Net Sales: N/A; Most recent Net Profit: N/A; Market-cap value: INR 537 Cr (Micro Cap).<BR><BR>Key Metrics: P/E: 26.00; Industry P/E: 34; Dividend Yield: 0.00%; Debt-Equity: -0.27; Return on Equity: 20.39%; Price-to-Book: 5.35.<BR><BR>Contact Details: Registrar Address: Not available; Phone: N/A; Email: N/A; Website: N/A.

Who are the peers of the Influx Health.?

Influx Health's peers include Sigachi Industries, Anuh Pharma, Kilitch Drugs, Zim Laboratories, Amanta Healthcare, Haleos Labs, Bafna Pharma, Jenburkt Pharma, and CCME Global. Management risk varies from excellent to below average among peers, with Bafna Pharma showing the highest 1-year return at 134.10% and Sigachi Industries the lowest at -62.44%.

Peers: The peers of Influx Health are Sigachi Indust., Anuh Pharma, Kilitch Drugs, Zim Laboratories, Amanta Healthcar, Haleos Labs Limi, Bafna Pharma, Jenburkt Pharma, CCME Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sigachi Indust., Anuh Pharma, and Jenburkt Pharma, while Average management risk is found at Influx Health, Zim Laboratories, Amanta Healthcar, Haleos Labs Limi, and CCME Global, and Below Average management risk is noted at Kilitch Drugs, Bafna Pharma, and the rest. Growth is rated as Excellent for Kilitch Drugs, Good for Influx Health, and Below Average for Sigachi Indust., Anuh Pharma, Zim Laboratories, Amanta Healthcar, Haleos Labs Limi, Bafna Pharma, and the rest. Capital Structure is Excellent for Sigachi Indust., Anuh Pharma, Influx Health, and Jenburkt Pharma, Good for Kilitch Drugs and Bafna Pharma, while Below Average is seen at Amanta Healthcar and Haleos Labs Limi, and Average at Zim Laboratories and CCME Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma at 134.10%, while the peer with the lowest is Sigachi Indust. at -62.44%. Influx Health's 1-year return is not available for comparison. Additionally, Haleos Labs Limi is the only peer with a six-month return that is negative.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.